Profile data is unavailable for this security.
About the company
WuXi AppTec Co Ltd is a China-based company principally engaged in the business of new drug research and development and manufacturing services. The Company conducts its business through six segments. The WuXi Chemistry Segment is primarily engaged in providing new drug research, development and manufacturing services. The WuXi Testing Segment is primarily engaged in providing pharmaceuticals, medical devices, and in vitro diagnostic reagents services. The WuXi Biology Segment is primarily engaged in providing drug discovery and research services. The WuXi ATU Segment is primarily engaged in providing customers with integrated medical product process development, manufacturing and testing services. The WuXi DDSU Segment is primarily engaged in providing customers with integrated new drug research and development services. The Other Segment is primarily engaged in administrative services, sales of raw materials and sales of waste materials.
- Revenue in HKD (TTM)48.27bn
- Net income in HKD18.76bn
- Incorporated2000
- Employees37.83k
- LocationWuXi AppTec Co Ltd228 Fute Zhong RoadWaigaoqiao Free Trade ZoneSHANGHAI 200131ChinaCHN
- Phone+86 2 150461000
- Fax+86 2 150463093
- Websitehttps://www.wuxiapptec.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.70bn | -817.00m | 96.21bn | 1.87k | -- | 16.96 | -- | 56.67 | -3.65 | -3.65 | 7.53 | 24.33 | 0.3067 | 4.93 | 13.37 | 924,201.40 | -14.76 | -- | -17.11 | -- | 57.10 | -- | -48.12 | -- | 6.32 | -- | 0.0255 | -- | 25.48 | -- | 53.54 | -- | -- | -- |
| Akeso Inc | 2.84bn | -957.10m | 96.90bn | 3.53k | -- | 12.97 | -- | 34.12 | -1.08 | -1.08 | 3.24 | 8.11 | 0.2115 | 0.7726 | 3.95 | 935,890.60 | -7.07 | -8.38 | -8.20 | -9.82 | 79.26 | -- | -33.46 | -33.18 | 4.01 | -536.98 | 0.4168 | -- | -53.08 | 97.39 | -125.37 | -- | 34.14 | -- |
| WuXi Biologics (Cayman) Inc | 22.69bn | 4.75bn | 167.57bn | 12.55k | 36.21 | 3.24 | 22.27 | 7.39 | 1.12 | 1.12 | 5.41 | 12.50 | 0.3442 | 6.36 | 3.06 | 1,804,194.00 | 8.45 | 7.98 | 10.57 | 9.95 | 42.65 | 42.71 | 24.54 | 25.82 | 2.69 | -- | 0.0943 | 0.00 | 9.63 | 36.21 | -1.28 | 27.05 | 3.97 | -- |
| BeOne Medicines AG | 40.36bn | -173.08m | 329.78bn | 11.08k | -- | 13.71 | -- | 8.17 | -0.1999 | -0.1999 | 24.49 | 20.40 | 0.7516 | 1.47 | 7.05 | 3,221,068.00 | -0.3223 | -22.78 | -0.4778 | -30.07 | 85.99 | 83.69 | -0.4289 | -72.74 | 2.17 | 4.50 | 0.2209 | -- | 56.19 | 55.91 | 25.87 | -- | 40.78 | -- |
| WuXi AppTec Co Ltd | 48.27bn | 18.76bn | 349.47bn | 37.83k | 19.26 | 4.66 | -- | 7.24 | 6.54 | 5.76 | 16.77 | 27.06 | 0.5054 | 4.73 | 3.81 | 1,224,650.00 | 19.85 | 13.47 | 24.73 | 17.14 | 47.41 | 39.61 | 39.28 | 25.53 | 2.46 | -- | 0.1128 | 29.16 | -1.97 | 24.12 | -0.47 | 43.29 | 9.60 | 37.70 |
